Antimicrobial Resistance (AMR) is a complex challenge, requiring a comprehensive approach to address it. Our identified strategies centre around:

**Research and Science**
- Initiatives to support access to a sufficient supply of quality-assured AMR-relevant products
- Antimicrobial stewardship to ensure that existing antimicrobials are used appropriately

**Antimicrobial Stewardship and Appropriate Use**
- Education and awareness raising
- Aligning product promotion to AMR stewardship
- Generating evidence and tools to support appropriate use
- Collecting and/or sharing surveillance data

**Access**
- Product registration with regulatory authorities
- Ease of access
- Product availability
- Advocacy for approvals
- Ensuring high-quality products
- Inclusion in clinical guidelines
- Collaborative access mechanisms

**The Highlights**
- Alliance member contributions to tackling AMR (1 April 2021 and 31 March 2023)
- Approximately USD 2 billion was invested annually by 34 companies in 2021 and 2022 fiscal years.

**Looking to the Future**
- There is an urgent need for sustainable incentives to stimulate R&D at scale, to feed innovation pipelines and to help secure viable markets.
- Strengthening collaboration with the private, public, and not-for-profit sectors could support future Alliance activities to improve access to antimicrobials and enhance antimicrobial stewardship across diverse geographies.

The AMR Industry Alliance is a coalition of 77 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and 10 trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. The AMR Industry Alliance will ensure that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap and will measure progress made in the fight against antimicrobial resistance.

[amrindustryalliance.org](http://amrindustryalliance.org)